Programmable Sub-Viral Nanorobots for Precision Medicine - The MantaCell Platform Concept

Conventional systemic pharmacology — reliant on passive diffusion and imprecise pharmacokinetics — carries a well-documented and largely irreducible burden of mortality and disability. Across categories where global mortality is discretely tracked, cancer (an estimated 9.7 million deaths in 2022), chronic viral hepatitis and HIV/AIDS (1.3 million and 630,000 deaths respectively), and antimicrobial-resistant infection (1.27 million deaths in 2019) together account for approximately 12.9 million deaths annually, alongside a separately substantial burden of chronic disability from tissue damage that current therapeutics cannot reconstitute. This concept note proposes MantaCell, a target architecture for a fully programmable electromechanical nanorobot, 20–50 nm in outer hull diameter, intended for intravenous deployment in coordinated swarms capable of single-cell and molecular-level detection, targeted destruction, chemical scavenging, and structural tissue reconstruction. The proposed architecture integrates eight functional subsystems: a biomimetic lipid-coated carbon nanotube hull for immune evasion; glucose-biofuel-cell-powered piezoelectric propulsion; CRISPR-derived molecular detection arrays; modular chemical, photocatalytic, and scaffold-extrusion payload bays; programmable hull-surface docking proteins for swarm self-assembly; and a fully biodegradable, enzymatically-triggered clearance mechanism. Communication and navigation are proposed via an acoustic (ultrasonic) relay network, rather than radiofrequency transmission, reusing the platform’s piezoelectric actuators as dual-purpose transducers in a multi-hop swarm mesh — a design choice intended to avoid the antenna-size mismatch and tissue attenuation that make gigahertz-band RF impractical at this scale. A three-tier safety architecture (dead-man protocol, dose-limiting self-counting, and three independent kill switches) and cryptographically authenticated command signalling are proposed throughout. Each individual component technology — glucose-powered nanoswimmers, biomimetic immune-evasive coatings, CRISPR-based molecular detection, DNA-origami fabrication, and acoustic intra-body communication — corresponds to active, peer-reviewed research, but no research group has yet integrated them into a single operating platform. Nanobots Therapeutics’ enzyme-powered MotionTx platform represents the most scientifically and commercially advanced comparator identified and is proposed as the primary reference point for any freedom-to-operate and novelty assessment. Two unresolved scientific frontiers — autonomous directional navigation against Brownian motion at this scale, and the component density required to integrate sensing, power, propulsion, communication, and payload systems within a sub-100nm volume — are identified as the central determinants of overall platform feasibility. The programme is in the conceptual and early pre-prototype stage. No component of the platform has yet been fabricated or tested in integrated form, and a five-phase development roadmap spanning prototype validation through pivotal efficacy trials is proposed but not yet underway. This abstract, and the concept note it summarises, do not constitute a claim of technical feasibility, regulatory approval, or clinical performance. Keywords: nanorobotics; nanomedicine; precision medicine; programmable nanorobots; targeted drug delivery; CRISPR molecular diagnostics; biomimetic nanoparticles; immune evasion; glucose biofuel cell; piezoelectric propulsion; acoustic intra-body communication; ultrasonic nanonetworks; swarm robotics; self-assembly; DNA origami; tissue regeneration; antimicrobial resistance; oncology nanotherapeutics; biodegradable nanomaterials; medical device safety architecture.